Lumida
/AMLX
⌘K
Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc

AMLX
$31.62USD-1.46%-0.47 today

MARKET CAP

4.0B

P/E (TTM)

FWD P/E

DAY RANGE

$31 – $33

52W RANGE

$11
$41

AI Summary

Stalk
Sell NowMedium

AMLX has entered a Stage 3 distribution phase after a parabolic rally and now consolidates below its declining 9- and 20-day EMAs. Price has slipped below short-term moving averages with light volume, indicating rejection at resistance and lack of strong distribution support. Medium-term bias is bearish under the distribution regime, while the long-term uptrend remains intact above the 50- and 200-day SMAs but is currently overshadowed by near-term weakness.

  • Phase III Lucidity trial showed significant reduction in hypoglycemic events, driving a 47% share rally.
  • Avexitide targets ~160k U.S. post-bariatric hypoglycemia patients; endocrinologist surveys show strong treatment intent.
  • FDA approval uncertainty looms over Avexitide’s planned 2027 launch.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2022FY 2023FY 2024TREND
Sales, Adj.$22.2M$380.8M$87.4M
YoY %+1612.9%-77.1%
P / Sales94.7x2.8x2.9x
EV / Sales94.2x2.5x2.4x
Gross Profit, Adj.$19.2M$355.3M$81.4M
YoY %+1747.2%-77.1%
Margin %86.5%93.3%93.2%
EV / Gross Profit108.8x2.7x2.6x
EBITDA, Adj.$-200.9M$39.9M$-172.3M
YoY %+119.9%-531.9%
Margin %-903.5%10.5%-197.2%
EV / EBITDA-10.4x24.1x-1.2x
EBIT$-201.3M$38.8M$-314.7M
YoY %+119.3%-911.1%
Margin %-905.7%10.2%-360.2%
EV / EBIT-10.4x24.8x-0.7x
Net Income$-198.4M$49.3M$-301.7M
YoY %+124.8%-712.4%
Net Margin-892.4%12.9%-345.4%
EPS (GAAP)-$3.39$0.70-$4.43
YoY %+120.6%-732.9%